SCHEMBL2995496

SCHEMBL2995496

CC(=O)CC1=CCOCC1

nearest known ligand 0.33

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
MAPK1 P28482 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12045440 0.77 MTNR1A (0.38) MAPK1
SCHEMBL989411 0.74
SCHEMBL11359025 0.73
SCHEMBL10299844 0.73
SCHEMBL18951911 0.71
SCHEMBL13901144 0.69
SCHEMBL1563795 0.69
SCHEMBL12026404 0.69 ERCC1 (0.39)
SCHEMBL17187583 0.69 PIK3CD (0.35) MAPK1
SCHEMBL24713288 0.69

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-110167944-B Substituted pyrazoloazepin-4-ones and their use as phosphodiesterase inhibitors 联合疗法公司 2024-08-23 CN disclosed
CN-110088108-B Substituted pyrazoloazepin-4-ones and their use as phosphodiesterase inhibitors 联合疗法公司 2024-06-14 CN disclosed
EP-3551632-B1 SUBSTITUTED PYRAZOLOAZEPIN-4-ONES AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS UNION THERAPEUTICS AS (DK) 2024-06-12 EP disclosed
US-20220362259-A1 SUBSTITUTED PYRAZOLOAZEPIN-4-ONES AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS UNION therapeutics A/S (DK) 2022-11-17 US disclosed
US-11065257-B2 Substituted pyrazoloazepin-4-ones and their use as phosphodiesterase inhibitors LEO PHARMA A/S (DK) 2021-07-20 US disclosed
US-11065257-B2 Substituted pyrazoloazepin-4-ones and their use as phosphodiesterase inhibitors LEO PHARMA A/S (DK) 2021-07-20 US disclosed
EP-3551633-B1 SUBSTITUTED PYRAZOLOAZEPIN-4-ONES AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS LEO PHARMA AS (DK) 2021-03-31 EP disclosed
EP-3551633-B1 SUBSTITUTED PYRAZOLOAZEPIN-4-ONES AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS LEO PHARMA AS (DK) 2021-03-31 EP disclosed
US-10906915-B2 Substituted pyrazoloazepin-4-ones and their use as phosphodiesterase inhibitors LEO PHARMA A/S (DK) 2021-02-02 US disclosed
US-10906915-B2 Substituted pyrazoloazepin-4-ones and their use as phosphodiesterase inhibitors LEO PHARMA A/S (DK) 2021-02-02 US disclosed
US-20200323869-A1 SUBSTITUTED PYRAZOLOAZEPIN-4-ONES AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS LEO PHARMA A/S (DK) 2020-10-15 US disclosed
US-20200323869-A1 SUBSTITUTED PYRAZOLOAZEPIN-4-ONES AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS LEO PHARMA A/S (DK) 2020-10-15 US disclosed
US-20200123127-A1 REMOVAL OF SENESCENCE-ASSOCIATED MACROPHAGES EVERON BIOSCIENCES, INC. 2020-04-23 US disclosed
EP-3551633-A1 SUBSTITUTED PYRAZOLOAZEPIN-4-ONES AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS Leo Pharma A/S (DK) 2019-10-16 EP disclosed
WO-2018108230-A1 SUBSTITUTED PYRAZOLOAZEPIN-4-ONES AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS LEO PHARMA A/S (DK) 2018-06-21 WO disclosed
WO-2017189553-A1 REMOVAL OF SENESCENCE-ASSOCIATED MACROPHAGES EVERON BIOSCIENCES, INC. (US) 2017-11-02 WO disclosed
US-8084649-B2 Herbicides SYNGENTA CROP PROTECTION, INC. (US) 2011-12-27 US disclosed
US-20100173774-A1 NOVEL HERBICIDES SYNGENTA CROP PROTECTION, INC. (US) 2010-07-08 US disclosed
EP-2121584-A2 NOVEL HERBICIDES Syngeta Participations AG (CH) 2009-11-25 EP disclosed
WO-2008110308-A2 NOVEL HERBICIDES SYNGENTA PARTICIPATIONS AG (CH) 2008-09-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10906915-B2 Substituted pyrazoloazepin-4-ones and their use as phosphodiesterase inhibitors PDE4A, PDE4B, PDE12 MAPK1 2444/4885
US-20200323869-A1 SUBSTITUTED PYRAZOLOAZEPIN-4-ONES AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS PDE4A, PDE4B, PDE12 MAPK1 2444/4885
US-20220362259-A1 SUBSTITUTED PYRAZOLOAZEPIN-4-ONES AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS PDE4A, PDE4B, PDE12 MAPK1 2444/4885
US-11065257-B2 Substituted pyrazoloazepin-4-ones and their use as phosphodiesterase inhibitors PDE4A, PDE4B, PDE12 MAPK1 2444/4885
US-20200123127-A1 REMOVAL OF SENESCENCE-ASSOCIATED MACROPHAGES CD68, CD47, ARG1 MAPK1 2497/4885
US-20100173774-A1 NOVEL HERBICIDES DDT, HDHD5, HPD MAPK1 3934/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.